No Data
No Data
Palisade Bio Secures CAD$1.39 Million in SR&ED Funding for PALI-2108 Development Efforts
Express News | Palisade Bio, Inc. Announces Receipt of Cash Proceeds From Canada’s SR&Ed Tax Incentive Program for Reimbursement of Development Costs of Pali-2108 for Treatment of Ulcerative Colitis (Uc)
Palisade Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio Selected For Poster Presentation At The 2025 Crohn's & Colitis Congress February 6-8, 2025